arrow
A

Angela Toss

istituti clinici scientifici maugeri irccs
H指数:31
被引数:3,344

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Legal Frameworks, Institutional Barriers and Unmet Needs of Young University Students With Cancer in Italy: A Call to Action

意大利年轻癌症大学生的法律框架、制度障碍和未满足的需求:行动呼吁

2026-10-230
OA
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY

年轻乳腺癌患者BRCA1/2致病性或可能致病性变异的类型和位置与表型和预后之间的关系: 一项国际队列研究的结果

2025-11-170
OAAI
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers

年轻BRCA携带者在孕期被诊断患有乳腺癌后,再次怀孕的安全性

2025-08-130
OAAI
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
2025-04-080
OAAI
Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome

患有遗传性乳腺癌和/或卵巢癌综合征的年轻健康女性的生殖潜力降低

2025-03-080
OAAI
Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study

乳腺癌年轻BRCA携带者产后哺乳:一项国际队列研究的结果

2024-09-010
PRE
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (vol 10, 58, 2024)

药物-药物相互作用对abemaciclib在AB-意大利研究的真实世界经验中的临床影响 (第10卷,58卷,2024)

2024-08-020
OAAI
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

在AB-意大利研究的现实世界经验中,药物-药物相互作用对abemaciclib的临床影响

2024-07-173
OAAI
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study

新辅助帕妥珠单抗、曲妥珠单抗和标准化疗治疗HER2-positive早期乳腺癌的安全性和有效性分析: 来自NeoPowER研究的真实数据

2024-06-151
OAAI
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
CANCER
IF5.1
2024-05-166
OAAI
CDK4/6 inhibitors in advanced breast cancer (aBC). Preliminary results of the CDK4/6i choice and sequence of treatments in a series of 174 patients. GOIRC-04-2019 retro/prospective observational study
2024-05-020
PRE
Pregnancy After Breast Cancer in Young BRCA Carriers
2024-01-0220
OA